1 of 1
HOUSE DOCKET, NO. 2183 FILED ON: 1/15/2025
HOUSE . . . . . . . . . . . . . . . No. 2200
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Marjorie C. Decker
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act relative to the prescription monitoring program.
_______________
PETITION OF:
NAME:DISTRICT/ADDRESS :DATE ADDED:Marjorie C. Decker25th Middlesex1/15/2025 1 of 2
HOUSE DOCKET, NO. 2183 FILED ON: 1/15/2025
HOUSE . . . . . . . . . . . . . . . No. 2200
By Representative Decker of Cambridge, a petition (accompanied by bill, House, No. 2200) of
Marjorie C. Decker relative to the administration of opioid maintenance treatment in the
prescription monitoring program. Mental Health, Substance Use and Recovery.
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninety-Fourth General Court
(2025-2026)
_______________
An Act relative to the prescription monitoring program.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
of the same, as follows:
1 SECTION 1. Section 24A of chapter 94C of the General Laws, as appearing in the 2022
2Official Edition, is hereby amended by inserting after subsection (c) the following subsection:-
3 (c½) The department shall establish, by rule or regulation, a process by which to include
4information about the administration of opioid maintenance treatment in the prescription
5monitoring program, when the inclusion of such information does not conflict with state or
6federal privacy rules. The purpose of this subsection shall be to ensure that licensed professionals
7authorized to prescribe controlled substances receive information, through utilization of the
8prescription monitoring program, about an individual patient’s participation in opioid
9maintenance treatment prior to issuing a new prescription for an opioid substance other than the
10substance used for opioid maintenance treatment.
11 SECTION 2. Section 18 of chapter 111E of the General Laws, as appearing in the 2022
12Official Edition, is hereby amended by inserting after subsection (a) the following subsection:- 2 of 2
13 (a½) For each facility that is an opioid treatment program, as defined under 42 CFR Part
148, the facility shall present to each individual entering treatment a form that allows the individual
15to consent to the release of information, through the prescription monitoring program, about the
16administration of opioid maintenance treatment at the facility. Said consent form shall be
17accompanied by information clearly explaining that such consent is not required but is
18encouraged to improve coordination of services; and by information on how the individual may
19complete and return the form to the facility or to the department of public health if they elect to
20give such consent. A record of the individual’s election relative to this form shall be maintained
21by the facility as part of the record of treatment required by this section. The same form and
22information shall be presented to the individual upon their discharge from the facility.